Technical Data
B0003-05L7
Bacillus anthracis LF (Lethal Factor) Protein (Anthrax)
Description:
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) (3) and capillary morphogenesis protein 2 (CMG2) (4), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm (5). LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis (6).

Applications:
Can be used for the detection of Anthrax LF protein in ELISA. It will detect 10 ng of free peptide at 1ug/ml.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Store at -20°C or colder. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceRabbit
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to 16 amino acids in the middle of the Anthrax lethal factor protein (Genbank accession no. P15917).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.02% sodium azide.
Specificity:
Recognizes Anthrax LF (IN).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schwartz MN. Recognition and management of anthrax – an update. New Engl. J. Med. 2001; 345:1621-6. 2. Moayeri M and Leppla SH. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 2004; 7:19-24. 3. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414:225-9. 4. Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003; 100:5170-4. 5. Singh Y, Klimpel KR, Goel S, et al. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytotic uptake into mammalian cells. Infect. Immun. 1999; 67:1853-9. 6. Duesbury N, Webb C, Vande Woude G, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-6.